Developing innovative strategies for treating resistant cancers
Founded in 2020 by Prof. Y. Ben-Ari, B&A Oncomedical is a startup driven by the ambition to develop a groundbreaking approach for treating complex and resistant tumors. We believe that targeting the tumor alone is not enough; instead, we embrace an innovative vision that considers the neural environment and the hyperexcitability that promote tumor progression.
Using cutting-edge ex vivo and in vitro models, we delve deep into the mechanisms underlying brain tumors. Our research paves the way for new therapeutic strategies, not only for resistant tumors but also for other diseases where chloride homeostasis dysregulation plays a key role.
Our research projects
A combined approach to target the tumor and its microenvironment
An innovative therapeutic combination of two compounds aimed at destroying tumor cells while targeting their interaction with the neuronal environment.
New NKCC1 inhibitors: Multiple applications and more effective
A new generation of more effective NKCC1 inhibitors offers promising prospects for the treatment of brain tumors and disorders linked to the deregulation of chloride homeostasis.
